Tvardi Therapeutics (TVRD) Current Leases (2019 - 2026)

Tvardi Therapeutics (TVRD) posted Current Leases of $120000.0 for Q1 2026, up 3.45% sequentially from $116000.0 in Q4 2025.

Tvardi Therapeutics (TVRD) Current Leases (2019 - 2026) Analysis & Trends

Tvardi Therapeutics has reported Current Leases for 8 years, with the latest figure at $120000.0 in Q1 2026.

Quarterly Current Leases changed N/A year-over-year to $120000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $120000.0 (changed N/A YoY) and the FY2025 annual result came in at $116000.0, up 12.62% from the prior year.
Current Leases advanced to $120000.0 in Q1 2026 per TVRD's latest filing, from $116000.0 in the prior quarter.
Over five years, Current Leases peaked at $3.4 million in Q3 2024 and troughed at $103000.0 in Q4 2024.
A 5-year average of $981666.7 and a median of $497000.0 in 2023 frame the typical range for Current Leases.
The sharpest annual moves came in 2024 and 2025: Current Leases jumped 587.53% in 2024, then plunged 96.69% in 2025.
Over 5 years, Current Leases stood at $1.9 million in 2022, then plunged by 74.09% to $497000.0 in 2023, then plunged by 79.28% to $103000.0 in 2024, then rose by 12.62% to $116000.0 in 2025, then grew by 3.45% to $120000.0 in 2026.
According to Business Quant data, Current Leases over the past three periods registered $120000.0, $116000.0, and $113000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	720.00 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	21.95 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	45.93 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Tvardi Therapeutics	17.36 Mn	17.36 Mn	-	123,000.00

Download Data